Abstract:
A particle includes a copolymer of lactic acid and glycolic acid, and at least one compound selected from silicon naphthalocyanine and derivatives of silicon naphthalocyanine, in which the particle has a particle size of 10 nm or more and less than 1000 nm.
Abstract:
First, a coloured solution is claimed, comprising at least one perfluorocarbon as a solvent and a dye dissolved in the perfluorocarbon and selected from the family of fluorinated derivatives of phthalocyanines obtained by substituting one or more of the hydrogen H atoms linked to the benzene rings with a fluorine atom or a fluorinated group, for use in surgical methods for the treatment of the bodies of humans or animals, in particular in surgical methods of vitreoretinal surgery where the coloured solution acts as a retinal tamponade. Second, a coloured solution is claimed, comprising at least one perfluorocarbon selected from perfluorooctane, perfluorodecalin and perfluorophenanthrene as a solvent and a dye dissolved in the perfluorocarbon and selected from the family indicated above. The dye, in general, is preferably selected from the family of metalpoly(fluoroalkyl)phthalocyanines and even more preferably of metalpoly(perfluoroalkyl)phthalocyanines.
Abstract:
This invention relates to the diagnosis of abnormalities of the epithelial-lined surface of the esophagus and, in particular, to the use of esters of 5-aminolevulinic acid (5-ALA) in methods of photodynamic diagnosis (PDD) of Barrett's esophagus and in diagnostic methods which monitor the progression of the disease with high specificity.
Abstract:
RGD-chlorophyll and RGD-bacteriochlorophyll conjugates that home and accumulate in necrotic tumor domains much longer than in tumor non-necrotic domains are provided for use in minimally invasive tumor-targeted imaging, tumor-targeted photodynamic therapy, and/or on-line prognosis of necrotic tumors.
Abstract:
An apparatus and method for noninvasive measurement of a fluorescent analyte concentration in the blood of a patient by exciting the blood and the analyte at two wavelength ranges and measuring the emission spectrum of the fluorescent analyte when (i) the difference of emission intensities at the excitation wavelength ranges of the fluorescent analyte is greater than that of background fluorophores, and (ii) when blood absorbance at the two excitation wavelength ranges is similar. An apparatus and method for measurement of a fluorescent analyte concentration in the blood of a patient is provided.
Abstract:
A new class of micro- and nano-particulate paramagnetic spin probes especially useful for magnetic resonance imaging techniques, including electron paramagnetic resonance (EPR) and magnetic resonance imaging (MRI). The probes are lithium phthalocyanine derivative compounds. Also provided are suspensions and emulsions comprising lithium phthalocyanine derivative probes. Also provided are noninvasive methods for measuring noninvasive methods of measuring oxygen concentration, oxygen partial pressure, oxygen metabolism, and nitric oxide concentration in a specific tissue, organ, or cell in vivo or in vitro.
Abstract:
A method of detecting a contrast agent for photoacoustic imaging provides a high signal intensity. In a contrast agent for photoacoustic imaging, each particle containing an inorganic material supports at least an organic dye having an absorption coefficient in the near infrared region by means of chemical bonding.
Abstract:
An object of the present invention is to increase the dye content in nanoparticles and to improve the signal intensity per particle. According to the nanoparticle including at least a silicon naphthalocyanine or a derivative thereof and a surfactant, wherein the proportion of the silicon naphthalocyanine or the derivative thereof is 70% or more by weight in relation to the other component of the particle exclusive of the surfactant, the dye content in the nanoparticles can be increased and the signal intensity per particle can be improved without weakening the signal intensity per dye molecule (light absorptivity)
Abstract:
A compound that is a conjugate of an antagonist to an integrin expressed by a tumor cell and at least one of a tumor avid tetrapyrollic photosensitizer, a fluorescent dye, and a radioisotope labeled moiety wherein the radioisotope is 11C, 18F, 64Cu, 124I, 99Tc, 111In or GdIII and its method of use for diagnosing, imaging and/or treating hyperproliferative tissue such as tumors. Preferably the photosensitizer is a tumor avid tetrapyrollic photosensitizer, e.g. a porphyrin, chlorin or bacteriochlorin, e.g. pheophorbides and pyropheophorbides. Such conjugates have extreme tumor avidity and can be used to inhibit or completely destroy the tumor by light absorption. The integrin is usually αvβ3, α5β1, αvβ5, α4β1, or α2β1. Preferably, the antagonist is an RGD peptide or another antagonist that may be synthetic such as a 4-{2-(3,4,5,6-tetra-hydropyrimidin-2-ylamino)ethyloxy}-benzoyl]amino-2-(S)-amino-ethyl-sulfonylamino group. Such compounds provide tumor avidity and imaging ability thus permitting selective and clear tumor imaging.
Abstract:
This invention relates to dry pharmaceutical compositions comprising an active ingredient which is 5-aminolevulinic acid (5-ALA) or a precursor or derivative of 5-ALA, or a pharmaceutically acceptable salt thereof. The compositions may be used in the photodynamic treatment (PDT) or photodynamic diagnosis (PDD) of cancer, pre-cancerous conditions and non-cancerous conditions. The invention relates further to irradiation devices comprising dry compositions and the use of such devices in the photodynamic treatment (PDT) or photodynamic diagnosis (PDD) of cancer, pre-cancerous conditions and non-cancerous conditions.